培训资料下载中心
在线调研中心

  • 胡爱荣
    宁波肝病医院
    “我成功因为我志在成功!”
  • 郑小庆
    宁波肝病医院
    “尽自己所能,让自己满意!”
  • 谭俊
    宁波肝病医院
    “年轻没有失败,只要亮出风采!“
  • 李建芳
    宁波肝病医院
    “人之所以能,是相信能!“
  • 李明
    南昌大学附一医院
    “爱拼才会赢!”
  • 钟渊斌
    南昌大学附一医院
    “只要有斗志,不怕没战场。”
  • 张文峰
    南昌大学附一医院
    “自古成功在尝试。”
  • 高海兵
    福州传染病医院
  • 张元芬
    福州传染病医院
  • 郑玲
    福州传染病医院
  • 黄祖雄
    福州传染病医院
  • 陈洁
    福建175 医院
  • 陈雪婉
    福建175 医院
  • 徐成润
    福建175 医院
  • 何芳
    四川大学华西医院
  • 刘凯
    四川大学华西医院
  • 卢家桀
    四川大学华西医院
  • 王丽春
    四川大学华西医院
  • 张琼
    成都市传染病医院
  • 朱丽
    成都市传染病医院
  • 张鸿
    成都市传染病医院
  • 王莉妮
    成都市传染病医院
       

培训资料当前位置:首页知识传递 > 培训资料 >

Navigating the Maze of Hepatitis B Treatments

来源: 作者:Division of Gastroenterology, 时间:2009-06-09 点击:

ANNA SUK-FONG LOK

Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan

Abstract The ultimate goal of hepatitis B treatment is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC). Because clinical outcomes arise only after decades of infection, surrogate end points are used to determine the success of hepatitis B treatment. Standardizeddefinitions of treatment response were discussed in detail at the 2006 National Institutes of Health Workshop on “Management of Hepatitis B.”Currently, there are 6 approved therapies for hepatitis B virus (HBV) infection including 2 formulations of interferon, standard interferon α-2b (IFN-α-2b) and pegylatedinterferonα-2a (pegIFN-α-2a), and 4 nucleos(t)ideanalogues, lamivudine (Epivir), adefovir (Hepsera), entecavir(Baraclude), and telbivudine (Tyzeka). Despite these advances, approved treatments for hepatitis B do not eradicate hepatitis B virus. Thus, clinical benefit is dependenton the ability to maintain sustained suppression of HBV replication. However, long-term treatment with nucleos(t)ide analogues is associated with increasing rates of drug resistance, and the safety and efficacy of these therapies beyond 1-5 years have not been established. This review aims to help the reader navigate the maze of hepatitis B treatments. New therapies and molecularmechanisms of antiviral resistance are discussed in an accompanying article by Ghany and Liang.

论坛内相关帖子:

treatment algorithm for the management of chronic hepatitis B virus infection in the United States 2008 update


最新评论共有 1 位网友发表了评论
发表评论
评论内容:不能超过250字,需审核,请自觉遵守互联网相关政策法规。
用户名: